Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1127-1138

  Dai, Min ^a   Yip, Yuen Yee ^a   Hellstrom, Ingegerd ^a   Hellstrom, Karl Erik ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIBODY; CD137 ANTIGEN; CD19 ANTIBODY; CD19 ANTIGEN; CELL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; LARGE TUMOR; LONG TERM SURVIVAL; LUNG CARCINOMA; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MORTALITY; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; ANTIGENS, CD274; BIOMARKERS; CELL LINE, TUMOR; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAPERITONEAL; MICE; NEOPLASMS; TH2 CELLS; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84928818450     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1339     Document Type: Article

References (56)

1. Coley W. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hosp 1896;7:157.
2. Hellstrom KE, Hellstrom I. Cellular immunity against tumor specific antigens. Adv Cancer Res 1969;12:167-223.
3. Boon T, Cerottini JC, Van Den Eynde B, Van Der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
4. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
5. Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
6. Chen D, Mellman I. Oncology meets immunology: the cancer immunity cycle. Immunity 2013;39:1-10.
7. Galon J, Angell H, Bedognetti D, Marincola F. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013;39:11-26.
8. Couzin-Frankel J. Cancer immunotherapy. Science 2013;342:1432-3.
9. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
10. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331: 1565-70.
11. Linsley PS, Ledbetter JA. The role of the Cd28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.
12. Chen L, Ashe S, BradyWA, Hellström I, Hellström KE, Ledbetter JA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71: 1093-102.
13. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997;9:369-404.
14. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen LP. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106.
15. Leach DR, Krummel M, Allison J. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
16. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5.
17. Hellstrom I, Ledbetter JA, Scholler N, Yang Y, Ye Z,Goodman G, et al. CD3- mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc Natl Acad Sci U S A 2001;98:6783-8.
18. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-1- secretion. Nat Med 1999;5:1365-9.
19. Pilon-Thomas S, Mackay A, Vohra N, Mulé JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010;184:3442-9.
20. Fransen M, Sluijter M, Morreau H, Arens R, Melief C. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011;17:2270-80.
21. Curti B, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, et al. OX40 is a potent immune stimulating target in late stage cancer patients. Cancer Res 2013;73:7189-98.
22. Topalian SL, Drake CG, Pardoll D. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24: 207-12.
23. De Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7:411-23.
24. Morales-Kastresana A, Fernandez De Sanmamed M, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 2013;19:6151-62.
25. Hodi F, O'day S, Mcdermott D, Weber R, Sosman J, Haanen J, et al. Improved survival with ipilimumab in patients withmetastatic melanoma. New Engl J Med 2010;363:711-23.
26. Margolin K, Ernstoff MS, Hamid O, Lawrence D, Mcdermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13:459-65.
27. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McdermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
28. Brahmer JR, Tykodi SS, ChowLQ,HwuWJ, Topalian SL,HwuP, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
29. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma.New Engl JMed 2013;369:122-33.
30. Ascierto P, Simeone E, Sznol M, Fu Y, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010;37: 508-16.
31. Wen F, Thisted RA, Rowley C, Schreiber H. A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology 2012;1:172-8.
32. De Visser K, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
33. Baban B, Hansen AM, Chandler PR, Manlapa A, Bingaman A, Kahler DJ, et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell supppression via type I IFN signaling following B7 ligation. Int Immunol 2005;17:909-19.
34. Yang Y, Yang S, Ye Z, Jaffar J, Zhou Y, Cutter E, et al. Tumor cells expressing anti-CD137 SCFV induce A tumor-destructive environment. Cancer Res 2007;67:2339-44.
35. Dai M, Wei H, Yip Y, Feng Q, He K, Popov V, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother 2013;36:248-57.
36. Wei H, Zhao L, LiW, Fan K, QianW, Hou S, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLos ONE 2013;8: e84927.
37. Liu P, Jaffar J, Hellstrom I, Hellstrom KE. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother 2010;33:53-9.
38. Liu P, Jaffar J, Zhou J, Yang Y, Hellstrom I, Hellstrom KE. Inhibition of TGFbeta 1 makes nonimmunogenic tumor cells effective for therapeutic vaccination. J Immunother 2009;32:232-9.
39. Yang SC, Yang Y, Raycraft J, Zhang H, Kanan S, Guo Y, et al. Melanoma cells transfected to express CD83 induce anti-tumor immunity that can be increased by also engaging CD137. Proc Natl Acad Sci 2004;101: 4990-5.
40. Feng Q, Wei H, Morihara J, Stern J, Yu M, Kiviat N, et al. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol 2012;127:412-9.
41. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009;183:2475-83.
42. Dhodapkar M, Dhodapkar K, Palucka A. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ 2008;15:39-50.
43. Simpson T, Li F, Montalvo-Ortiz W, Sepulveda M, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-710.
44. Kohrt H, Houot R, Weiskopf K, Goldstein M, Lund P, Al E. Targeting CD137 to enhance the antitumor efficacy of cedtuximab by stimulation of innate and adaptive immunity. J Clin Oncol 2013;31:3015.
45. Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, et al. The HIF-1a hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov 2012;2:608-23.
46. Marabelle A, Kohrt H, Levy R. Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 2013;19:5261-63.
47. Lei C, Liu P, Chen B, Mao Y, Engelmann H, Shin Y, et al. Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J Am Chem Soc 2010;132:6906-7.
48. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118-22.
49. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008;8:74-80.
50. Jonsson G, Bursch C, Knappskog S, Geisler J, Miletic H, Ringner M, et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 2010;16:3356-67.
51. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
52. Schietinger A, PhilipM, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase. J Exp Med 2010;207:2469-77.
53. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010;17:121-34.
54. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
55. De Nardo D, Coussens L. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007;9:212.
56. Dilillo D, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010;184:4006-16.